Work

Phase 1 dose escalation study of CD34 selected CD19 directed CAR T with metabolic programming in relapsed/refractory B-cell lymphoma.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.2544

Authors: Brian Hess, Elizabeth Goodwin Hill, Lindsey Hendrickson, Kent Armeson, Nathaniel Oberholtzer, Tara Duke, Mary McGann, James A. Davis, Katherine Antel, Ashwath Gurumurthi, Mohammad Alhousani, Sara Goodwin, Lauren Pearce, Breanne Burke, Emma Kryway, Patrick J. Stiff, Nasheed Mohammad Hossain, Gina Scurti, Michael Nishimura, Shikhar Mehrotra

Institutions: Medical University of South Carolina, MUSC Hollings Cancer Center, Loyola University Chicago, University of Pennsylvania

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162524312

Cites:

Cited by:

Related to: